Quest Diagnostics (DGX) Tops Q2 EPS by 5c; Maintains FY Adjusted EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Jefferies Raises Price Target on Quest Diagnostics (DGX) to $86 Following 2Q Earnings Report
July 22, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Quest Diagnostics (NYSE: DGX), and raised the price target to $86.00 (from $75.00), following the company's 2Q earnings report. DGX posted its 3rd consecutive quarter of positive organic volume growth. However, pricing remains under pressure.
Analyst Brian Tanquilut... More
Quest Diagnostics (DGX) PT, Estimates Raised at Evercore ISI Amid Solid Q2
July 21, 2016 12:00 PM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Quest Diagnostics (NYSE: DGX) to $89.50 (from $78.50) but maintained a Hold rating following results.
The firm raised FY 2016 EPS from $5.10 to $5.15, FY 2017 EPS from $5.55 to $5.60 and FY 2018 EPS from $5.95 to $6.15.
Muken commented, "Quests turnaround momentum continues as volumes have stabilized in the LSD, with a consistent price headwind... More
